Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
51.31
+4.69 (10.06%)
After Hours: 51.49 +0.18 (0.35%)
Feb 27, 6:49PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 46.60 - 51.55
52 week 31.38 - 80.11
Open 46.73
Vol / Avg. 0.00/889,817.00
Mkt cap 4.45B
P/E     -
Div/yield     -
EPS -4.79
Shares 86.01M
Beta 2.69
Inst. own 95%
Feb 9, 2017
Q4 2016 Alnylam Pharmaceuticals Inc Earnings Release (Estimated)
Jan 9, 2017
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A
Jan 9, 2017
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 16, 2016
Alnylam Pharmaceuticals Inc R&D Day
Dec 4, 2016
Alnylam Pharmaceuticals to Discuss Clinical Results at ASH
Nov 30, 2016
Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -647.04% -869.63%
Operating margin -661.36% -900.33%
EBITD margin - -868.25%
Return on average assets -35.17% -30.96%
Return on average equity -46.81% -37.54%
Employees 514 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Michael P. Mason Chief Financial Officer, Principal Accounting Officer, Vice President, Treasurer
Age: 42
Bio & Compensation  - Reuters
Yvonne Greenstreet Chief Operating Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development
Age: 53
Bio & Compensation  - Reuters
.. Bartlett Keating Senior Vice President - General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Pushkal Garg M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 62
Bio & Compensation  - Reuters